Nasopharyngeal microbiome composition by SARS-CoV-2 presence and severity.

Publication date: Jul 02, 2025

The influence of SARS-CoV-2 on the nasopharyngeal microbiome, or vice-versa, is unclear. Nasopharyngeal swabs from Dutch healthcare workers (N = 257) and hospital outpatients with respiratory symptoms (N = 143), leftover after SARS-CoV-2 testing in 2020-2021, were 16S rRNA amplicon sequenced and tested for respiratory viruses by multiplex PCR panel. The healthcare workers were younger and much healthier than the patients, and experienced less severe viral infections. In the healthcare workers, log estimated concentrations (ECs) of Corynebacterium were slightly increased in samples with SARS-CoV-2 versus no virus detected, regardless of symptomatology (adjusted regression coefficient 0. 52, p = 0. 042) but no other bacterial ECs differed. Corynebacterium and Dolosigranulum ECs were higher in very mild/asymptomatic SARS-CoV-2 episodes compared to very mild/asymptomatic episodes with no viruses detected, but lower in mild compared to very mild/asymptomatic SARS-CoV-2 episodes (-1. 07, p = 0. 015, and -1. 37, p = 0. 011, respectively). In the patients, similar but non-significant trends by SARS-CoV-2 severity (fatal, severe, moderate versus mild) were seen for Dolosigranulum, but not for Corynebacterium. In this population, the largest nasopharyngeal microbiome composition differences were seen by the presence and severity of comorbidities. These findings suggest that the Dolosigranulum EC decreases with increasing SARS-CoV-2 severity, but the clinical relevance of this finding is unclear.

Open Access PDF

Concepts Keywords
Corynebacterium Adult
Healthier Aged
Outpatients Corynebacterium
Viruses COVID-19
COVID-19
Female
Health Personnel
Humans
Male
Microbiota
Middle Aged
Nasopharyngeal microbiome
Nasopharynx
Netherlands
Netherlands
RNA, Ribosomal, 16S
RNA, Ribosomal, 16S
SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
disease MESH viral infections
disease MESH clinical relevance
disease MESH COVID 19
disease IDO commensal
disease MESH otitis media
disease IDO susceptibility
disease MESH bacterial pneumonia
pathway REACTOME Influenza Infection
disease MESH influenza
drug DRUGBANK Coenzyme M
disease MESH infections
disease MESH RSV infection
disease IDO infection
disease IDO bacteria
disease MESH critically ill
disease MESH respiratory infections
drug DRUGBANK BCG vaccine
disease IDO pathogen
disease IDO history
drug DRUGBANK Oxygen
disease IDO assay
disease MESH parainfluenza
pathway KEGG Influenza A
disease IDO infectivity
drug DRUGBANK Water
disease IDO reagent
disease MESH asymptomatic infections
disease MESH Asthma
pathway KEGG Asthma
disease MESH comorbidity
disease MESH hypertension
disease MESH cystic fibrosis

Original Article

(Visited 6 times, 1 visits today)